Iino Kaiun Kaisha Ltd (9119.T) released earnings for its first half that Increased, from last year
The company's earnings came in at JPY12.110 billion, or JPY114.46 per share. This compares with JPY7.475 billion, or JPY70.65 per share, last year.
The company's revenue for the period rose 22.7% to JPY74.970 billion from JPY61.117 billion last year.
Iino Kaiun Kaisha Ltd earnings at a glance (GAAP) :
-Earnings: JPY12.110 Bln. vs. JPY7.475 Bln. last year.-EPS: JPY114.46 vs. JPY70.65 last year.-Revenue: JPY74.970 Bln vs. JPY61.117 Bln last year.
-Guidance:Full year EPS guidance: JPY 149.33Full year revenue guidance: JPY 149.000 B
All EPS are Basic
For comments and feedback contact: [email protected]
Business News
November 03, 2026 10:34 ET A key date in rare disease research. BridgeBio Pharma’s BBP-418 is under FDA Priority Review for limb-girdle muscular dystrophy type 2I/R9, a rare genetic disease with no approved treatment. The FDA decision is targeted for November 27. If approved, BBP-418 could become the first approved therapy for any form of limb-girdle muscular dystrophy.